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Summary.-A panel of 5 different breast-cancer and 2 other cancer extracts was
used to clarify the false-negative responses in patients with Stage I and II breast
cancer and the false-positive responses in control subjects. Most patients with
Stage I and II breast cancer who had an initially negative LAI response were positive
when tested against the panel. The false negatives occurred because of (1) the experi-
mental errors of the assay; (2) changes in the antigenic strength of the extracts; (3)
antigenic heterogeneity of a few tumours and (4) lack of tumour-specific reactivity
of the host. 3%0 of control subjects had a false-positive LAI response. The leucocytes
from most of these positive patients did not react to the panel of antigens, and hence
the false positives appeared to result from experimental error. In-hospital patients
with benign breast disease had a 12% positivity rate when initially assayed, and 63%
of these patients reacted to the panel of breast-cancer antigens. Those patients with
benign breast disease who reacted to the panel of breast-cancer antigens had cyto-
philic anti-breast-cancer antibody in their serum; their leucocyte LAI reactivity was
blocked in an immunologically specific manner by serum from advanced Stage IV
breast-cancer patients; their leucocytes reacted to extracts of breast cancer and not
fibrocystic breast tissue; their leucocyte reactivity was blocked by isolated breast-
cancer TSA that was linked to /2 microglobulin, but not by normal breast-tissue
proteins; and the kinetics of the LAI response after excision of the breast mass was
identical to that observed with breast-cancer patients after mastectomy. In these
patients, the breast tissue within the breast lump expressed breast TSA similar
to unequivocal breast cancer.
LEUCOCYTES from about 80°O of
patients with Stage I and II breast
cancer reacted in the tube LAI assay
(Grosser & Thomson, 1975; Flores et al.,
1977; Lopez et al., 1978) whereas leuco-
cytes from less than 500 of control sub-
jects reacted in the assay. Although the
latter figure was considered to result from
the variability of a biological assay, no
systematic study of the false-positive
patients had been undertaken to prove
that the patients were not, in fact,
sensitized to a breast-cancer antigen.
Conversely, there was no explanation why
a minority of patients with Stage I and 11
breast cancer did not react in the tube
LAI assay. In addition, patients with
benign breast disease had a higher rate
of LAI positivity (Lopez et al., 1978;
Flores et al., 1977) than other control
subjects, and this raised the possibility
that some of these patients were reacting
to breast-cancer antigens (Flores et al.,
1977; Lopez et al., 1978).
Because the tube LAI is a reliable
assay, reproducible in vitro, for the
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detection of sensitization to tumour-
specific antigens (Grosser & Thomson,
1975; Marti & Thomson, 1976; Flores et
al., 1977; Lopez et al., 1978; Thomson,
1978) these observations were considered
to be accurate, and the present study was
undertaken to define, if possible, the
reason for the false-positive and negative
LAI responses. To investigate these, the
leucocytes from the subject were reacted
against a panel of extracts of breast
cancer and unrelated tumour. The panel of
antigens was used on the assumption
that the leucocytes from a false-negative
patient might show reactivity to other
breast-cancer extracts if there was some
heterogeneity of breast-cancer tumour
antigens, or if the initial test antigen had
lost its activity. On the other hand, the
panel of antigens was used to test leuco-
cytes from patients who had false-
positive reactions, on the assumption that
if the leucocytes recognized a tumour-
specific antigen, they should react to
most other extracts of breast cancer. If
the positive response to the initial test
antigen resulted from some idiosyncrasy
of the initial test extract, or from experi-
mental error, an LAI response to different
breast-cancer extracts would not be expec-
ted. The validity ofthis approach for clari-
fying the false-positive and negative LAI
responses is shown in the results presented
in this study.
MATERIALS AND METHODS
Subjects.-The patients with false-positive
and negative LAI responses were drawn from
a total of 451 patients tested in the coded
study of Lopez et al. (1978).
Tumour extracts and tumour panels.-The
preparation of the cancer extracts has been
previously described in detail (Grosser &
Thomson, 1975; Marti & Thomson, 1976;
Flores et al., 1977; Lopez et al., 1978; Thom-
son, 1978). Four breast-cancer extracts were
prepared from metastatic deposits in the
liver from different postmortem specimens.
An extract was also prepared from 5 primary
breast cancers that were pooled. In 2 in-
stances, an extract was prepared from the
patient's own breast cancer. The nonspecific
antigens were prepared from metastatic
malignant melanoma and fibrocystic disease
of the breast. The breast-cancer and mela-
noma extracts were the panel against which
patients who had false-positive or false-
negative LAI responses were tested.
When a patient was tested against the
panel of antigens, a control subject and, if
possible, a breast-cancer patient whose
leucocytes were LAI+ were tested at
the same time. In addition, control subjects
and breast-cancer patients whose leucocytes
were LAI+ were tested with the panel
of extracts, to show that the leucocytes from
the breast-cancer patients reacted to each of
the breast-cancer antigens used in the panel,
and that the leucocytes from control subjects
did not react. The leucocytes to be tested
were coded and the code was broken at the
completion of the assay.
Protein concentration was determined by
the method ofLowry et at. (1951) with bovine
albumin as a standard. The protein concen-
tration of the specific and nonspecific
extracts was 100 ± 10 Hug per assay tube,
since this amount was optimal (Grosser &
Thomson, 1975; Marti & Thomson, 1976;
Flores et atl., 1977; Lopez et al., 1978; Thom-
son, 1978). Each sample oftumour extract for
the panel was used once and then dis-
carded; samples were stored at -40°C.
Antigen-induced tube leucocyte-adherence
inhibition (tube LAI) assay.-In a series of
test tubes, 106 peripheral-blood leucocytes
(PBL) were plated in the presence of
extracts of specific breast cancer, control
melanoma and Medium 199 as previously
described (Grosser & Thomson, 1975; Marti
& Thomson, 1976; Flores et al., 1977; Lopez
et al., 1978; Thomson, 1978). The tubes were
incubated horizontally at 37°C in a 5% CO2
humidified atmosphere and after 2 h the
number ofnonadherent cells was counted in a
haemocytometer and the nonadherence index
(NAI) was calculated as previously described
(Grosser & Thomson, 1975; & others).
An NAI value > 30 was positive, < 30 was
negative (Flores et al., 1977; Lopez et al.,
1978; Thomson, 1978).
Arming of control leucocytes by serum from
reactive patients.-PBL from control subjects
were preincubated with serum from reactive
breast-cancer patients, control subjects and
from the patient with benign breast disease
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whose leucocytes showed LAI reactivitv.
After preincubation with the serum, the
PBL were freed of excess serum by washing
twice with 10 ml of Medium 199, and then
plated in the standard antigen-induced tube
LAI assay (AMarti et al., 1976). The non-
adherent cells were counted after 2 h incuba-
tion and the NAI calculated.
Blocking of LAI activiry by serum and
papain-solutble antigens.-PBL from reactive
breast-cancer patients (Stages I and II),
from control subjects with negative LAI
assays, and from patients with benign
breast disease with a positive LAI assay,
were preincubated with serum from either
advanced nonreactive Stage IV breast-
cancer patients or cointrol subjects. After
incubation for 30 min at 37°C in a 50 C03
atmosphere, the cells were washed with 10 inl
of Medium 199 to remove excess serum, and
the PBL were then plated in the standard
tube LAI assay (Thomson, 1978; Grosser &
Thomson, 1976). After 2h incubation the
nonadherent cells were counted and the NAI
calculated. Papain-soluble material from the
membranes of breast-cancer, normal breast
tissue and melanoma were similarly tested
for blocking activity (Thomson, 1978; Thom-
son et al., 1978).
RESULTS
Table 11 of the paper by Lopez et al.
(1978) shows the results of a coded
study of the tube LAI assay in breast-
cancer patients and a variety of control
subjects. In Stage I and II breast cancer,
4/24 (17O%) and 7/26 (28%0) patients
respectively did not have leucocyte reacti-
vity in the tube LAI assay. In the group
of patients admitted to hospital with
breast masses which clinically were
thought to be breast cancer but turned
out to be benign breast disease (BBD), 9/
76 (12o%) had positive LAI, whereas in
the group of outpatients with benign
breast disease 1/41 (2%) had positive
LAI. To date, no breast cancers have
developed in either group of BBD pati-
ents. Control subjects with benign surgical
disease and unrelated cancer had 3/92
(3O%) and 4/138 (3%) respectively with
LAI reactivity.
To determine whether a panel of breast-
cancer extracts could be used to test
breast-cancer patients with limited cancer
who had a negative LAI response, and
patients without breast cancer who had
a positive LAI response, 5 breast-cancer
patients who were LAI+ and 5 control
subjects who were LAI- had their
leucocytes tested against the panel.
All samples of leucocytes were coded.
Since the PBL were tested against 5
breast-cancer and 2 melanoma antigens,
the combination resulted in 10 tests to
the breast cancers. The leucocytes from
5 breast-cancer patients showed positive
LAI activity to the 5 different breast-
cancer antigens in the panel, except for
one patient with a negative response to
one antigen. The leucocytes from the
5 control subjects had a positive response
in one of the tests to the breast cancer
antigens, which was a 4%0 rate of experi-
mental error. The results suggested that
the experimental error was low enough
for PBL responses to the panel of breast-
cancer extracts to be evaluated.
Throughout the year, leucocytes from
reactive breast-cancer patients and control
subjects were repeatedly tested against
the panel of antigens to continue to assess
the reproducibility of the panel. If leuco-
cytes from patients with limited malignant
melanoma were incubated with the
extracts of malignant melanoma (non-
specific) and breast cancer (specific), the
melanoma extracts produced specific anti-
gen-induced LAI. Classical criss-cross ex-
periments were not done routinely, because
it was virtually impossible to have
available at the same time patients with
breast cancer and melanoma who were
LAI+ to their respective tumours.
Breast-cancer patients (Stages I and II)
with an initial negative LAI, tested against
the panel of antigens
To investigate why some patients with
localized cancer (Stage I and II) had a
negative LAI before surgery, these pati-
ents were tested 3-4 weeks after surgery,
against a panel of 5 different breast-
cancer antigens and two nonspecific tum-FALSE POSITIVE AND NEGATIVE LAI ACTIVITY
TABLE I.-Test on breast-cancer patients with an initial negative LAI,
against a panel of breast-cancer antigens*
Diagnosis of
leucocyte clonor
and patieint, no.
Stage I (No. 3)
Stage I (No. 12)
Stage II (No. 41)
Stage I (No. 23)
Stage II (No. 3:7)
Stage II (No. 18)
Stage I (No. 32)
NAI to PBS
breast-cancer
extract (Wolf)
0
-2
4
15
15
:1
-10
Panel of breast-canicer antigeuist
Wolf April Pooled Arm.
-t
Patient's
own tumour
Eliz. AMcL Car.
-4r
Positive Conitrol 59) + + + +
Stage I
Negative Contr-ol -5
Positive Control :35 + + + +
Stage 11
* A breast-cancer patienlt with aInegative NAI, a cointrol subject and, ifpossible, a reactive breast-cancer
patient were tested against the panel of antigens with PBL samples coded. To siimplify the Table only 3
controls are incluided.
t Extracts of different breast cancers were used as the specific antigen ainl extracts of melainoma as the
inoinspecific aintigen. An NAI value > 30 is indicated by a +, < 30 by a -. The tube LAI assay is qualitative,
not quantitative.
our antigens. One of the 5 breast-cancer
antigens included in the panel was the
extract used in the initial test. Seven of
the 11 LAI- patients were tested against
the panel. Table I shows that of the 7
patients initially LAI- (4 Stage I and
3 Stage II) 6 had a positive LAI when
tested against the panel. Two of the 7
patients tested against the panel reacted
to the antigen (Wolf) used for the original
test, and to most of the other breast-
cancer antigens in the panel. Their
initial negative LAI therefore resulted
from experimental error.
By contrast, the other 5 initially LAI
results in the breast-cancer patients appear
to have different explanations. Patient
No. 23 reacted to 2/5 antigens, and an
identical result was observed when the
patient was tested 1 week later. However,
the patient showed strong LAI reactivity
to an extract of her own tumour on 3
separate occasions. The difference in
leucocyte nonadherence to the extracts of
the 3 breast cancers to which the patient
was positive and the two melanomas
was statistically significant (P < 0 001).
Interestingly, other LAI+ breast-cancer
patients reacted to an extract of Patient
No. 23's tumour (Table I). Conversely,
Patient No. 32 did not react to any of the
antigens in the panel, and also failed to
react to an extract of her own tumour,
whereas other reactive breast-cancer pati-
ents showed LAI reactivity to an extract
of Patient No. 32's tumour (Table I).
Hence, Patient No. 32's breast cancer
expressed a breast-cancer-specific antigen.
Serum from Patient No. 32 did not block
LAI activity of leucocytes from other
breast-cancer patients. Measurement of
cortisol receptors in the breast cancer
(Fazekas and MacFarlane, 1977; Fazekas
et al., 1978) (kindly performed by Dr
Fazekas, Dept. of Surgery) showed these
to be high.
The other 3 patients (Nos. 12, 41, 18),
when tested against the breast-cancer-
antigen panel, reacted to the other
breast-cancer antigens but failed to react
to the "Wolf" breast-cancer extract. The
failure to react to the "Wolf" extract in
Patient No. 12 was attributed to a partial
loss of antigenic activity of that extract,
since the patient subsequently reacted on
2 separate occasions to a fresh extract of
the "Wolf" breast cancer. Table I lists the
reactivity of leucocytes from the breast-
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TABLE II.-Summary of results detailed in Table I together with LAI results in
Stage IV breast-cancer patients
Panel of breast-cancer antigens
No. of patients
Diaginosis of initially No. LAI+ LAI-
leucocyte (donoi LAI tested No. (o) No. ( /)
Breast cancer
Stage 1 4 4 : (75) 1 (25)
Stage 11 7* 3 :3 (100) 1) (0)
Stage LV 28 5 0 (0) 5 (100)
*4 receivedladjuvant chemotherapyinthe 10 days before testing, anidwere therefore unsuitable for testing.
TABLEIII. Tests on patients with benign breast disease (BBD) with an
initial positive NVAI, against a panel of breast-cancer antigens
NAI to PBS Panel of breast-cancer antigens*
Diagniosis of turmour extract
leucocyte donor (Wolf) Wolf April Arm. Eliz. Pooled
BBD (No. 8)
BBD (No. 16)
BBD (No. 11)
BBD (No. 15)
BBD (No. 19)
BBD (No. 20)
BBD (No. 9)
BBD (No. 21)
Controls
- ve BBD
+ ye Breast-
cancer
-ve BBD by
mammography
* Pi-oce(lure as in Table 1.
54
35
40
57
51
39
75
96
-2
30
-4-
+
+
H-
4-
-iJ
+ + + +
8
cancer patients initially LAI- to the panel
ofbreast-cancer antigens. For comparison,
the LAI response of a few of the controls
(LAI+ patients with breast cancer and
LAI- control subjects) are also shown.
Table II summarizes the results of
Table I. Of Stage I patients 7500 were
LAI+ in spite of the failure to show this
in the initial test. Of Stage II patients,
3/7 were tested and all were LAI+.
Patients without breast cancer with an
initial positive LA! tested against the panel
of antigens
Patients with benign breast disease who
had an initial positive LAI were tested
against the panel of 5 breast antigens and
2 control-tumour antigens (Table III).
Eight of the 9 LAI+ patients with benign
breast disease were tested and 5 (63%)
reacted to the majority of breast-cancer
antigens in the panel. The remaining 3
patients (37%o) reacted to one or none
of the breast-cancer antigens in the panel,
i.e. they had initial false positives due to
experimental error.
In the patients with unrelated cancer,
3/92 were positive in the initial assay and,
when tested against the panel, 1 remained
positive, whereas the other 2 were nega-
tive (Table IV). The LAI+ patient was
originally admitted to hospital with a
breast lump which was proved by biopsy
to be due to fibrocystic disease, but
shortly after the biopsy the patient
underwent laparotomy and ovarian cari-
noma with metastasis in the omentum
was found. Four of 138 (3%) patients
with nonmalignant surgical diseases tested
in the tube LAI were positive. One of
these patients, a male with an inguinal
hernia, was positive against the panel of
breast-cancer antigens; however, when
tested several months later he was LAI-.
The patient denied any contact with
patients with breast cancer. The other 3
patients were negative when tested against
the panel, and the initial positive LAIsFALSE POSITIVE AND NEGATIVE LAI ACTIVITY
TABLE IV. Summary of test on patients without breast cancer who had
an initial positive LAI, against a panel of breast-cancer antigens
Diagnosis of
leucocyte donors
BBD
Unrelated
cancers
Nonmalignant
(lisease
BBD from
mammography
clinic
Total No.
tested
76
92
138
41
No.
initially LAIP
9
3
4
1
Panel of breast-cancer antigens
__ _ A
No. LAI+ LAI-
teste(d No. (%o) No. (%)
8 5 (63) .3 (37)
:X 1 (33) 2 (66)
4 1 (25) :3 (75)
] ( (0) I (100)
TABLE V. Results of blocking and arming with serum and leucocytes respectively,
on BBD patients who reacted to the panel of antigens
Donor of le
leucocytes
Breast cancer
patient (BCP)
BBD: LAITh
Control (Con)
subject
* > 30 is positive; < 30 is negative.
NAI of
P,ucocyte
(lonor
41
Donor leucocytes
preiincubate(d with
serum from:
Metastatic BCP
Metastatic melanoma
patient
Con
49 Metastatic BCP
Metastatic melainoma
patient
Con
-8 Reactive BCP
BBD: LAI
Con
were considered to be the result of
experimental error (Table IV).
LAI+ BBD patients
PBL from the BBD patients who were
positive against the panel were tested in
the blocking tube LAI assay with serum
from both patients with advanced breast
cancer and normal subjects. The LAI
activity of the reactive cells from BBD
patients was blocked by serum from
advanced breast-cancer patients but not
from control subjects (Table V). Moreover,
the blocking was immunologically specific,
since serum from nonreactive patients
with Stage IV melanoma did not block
the LAI activity. Similarlv, serum from
LAI+ BBD patients was able to arm leu-
cocytes from control subjects to react in
the tube LAI assay in an immunologically
specific manner against the breast-cancer
extract (Table V). Arming and blocking
NAI* after
incubation
1
35
40
6
54
41
42
46
4
was demonstrated in all 4 patients
tested. This pattern was similar to that
in LAI+ patients with Stage I and II
breast cancer (Table V).
To determine whether LAI+ and LAI-
BBD patients showed any difference in
the histological appearance of their fibro-
cystic disease, the histological sections
from 10 LAI- and 5 LAI+ BBD patients
were reviewed blindly by D.M. and were
scored with respect to degree of atypia
in the duct linings, according to the criteria
described by Black et al. (1972). The
LAI- BBD patients were scored as 2 or
less, whereas 2 of the 5 LAI+ BBD
patients were scored as 3 to 4, and 2 were
scored as 2.
Table VI shows that breast-cancer
patients react to extracts of breast-cancer
antigen but not of normal breast tissue
containing fibrocystic disease from an
LAI- patient. Similarly, the LAI+ BBD
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TABLE VI.-Reactivity of leucocytes of LAI+ breast-cancer patients and BBD patients
to extracts of breast cancer, fibrocystic disease (FCD) and control tumour (melanoma)
Diagnosis of
leucocyte donor
Breast cancer
(Stage I)
BBD-LAI+
Control subject A
B
Mean No. ± s.d. of nonadherent cells*
to extracts of:
A~~~~~
Breast
cancer FCD Mel
42±5 31±3 30±3
45±5
53± 9
38±4
32±3 29±2
51±8 54±11
32±3 36±4
NAIt to
Br.Ca. Br.Ca.
FCD Mel
34(P < 0 05) 43(P < 0 02)
41(P < 0.02)
4 (NS)
19 (NS)
55(P < 0-005)
-2 (NS)
6 (NS)
* All extracts were used at 100 ,ug/assay tuibe.
t Br.Ca. extract of breast cancer (Br.Ca.) as specific antigen and the extract of FCD as nonspecific
FICD antigen.
Br.Ca. xtract of malignant melanoma as the nonspecific antigen. Mel
Statistical significance of results calculated by Student's t test. NS; P > 0-05.
TABLE VII.-Blocking Tube LAI to demonstrate reactivity ofLAI+ BBD
patients to papain-soluble breast-cancer antigen
Diagnosis of
leucocyte donor
Br. Ca.
BBD: LAI+
Br. Ca.
BBD: LAI+
NAI to
PBS
extract
48
55
67
38
Donor leucocytes preincubated with:
Papain-solubilized membranes of*
Br. Ca.
Normal breast tissue
Malignant melanoma
Br. Ca.
Normal breast tissue
Malignant melanoma
Anti-human fl2m affinity fractions oft
Br. Ca.
UJnbound
Bound$:
Melanoma
Bound
Br. Ca.
Unbound
Bound
Melanoma
Bound
NAI
after
blocking
5
59
40
0
47
62
51
2
59
42
8
33
* Membranes were isolated from the tissues listed and the membrane proteins were solubilized by papain.
The breast-cancer antigenic activity was then isolated by DEAE cellulose and Sephadex G-150 chromato- graphy as previously described (Thomson et al., 1976). Material from Sephadex G-150 Fraction 2 (70,000-
150,000 mol. wt) was used in the blocking assay with 100 ,ug of protein added to the preincubation tubes in
the presence of 5% FCS.
t Fraction 2 was then isolated by anti-human 92m affinity chromatography as previously described (Thomson et al., 1976, 1978). In the blocking assay 200 [Lg of protein from the unbound and 50 tLg from the
bound fraction were added to the preincubation tubes in the presence of 5% FCS.
$ When preincubated with LAI+ leucocytes from patients with colon cancer or malignant melanoma, the bound material did not abrogate their specific reactivity.
patient reacts to the extract of breast
cancer and not to the extract of breast
tissue containing fibrocystic disease.
A more definitive and sensitive test of
whether the LAI+ patient with BBD was
reacting to a TSA ofbreast cancer and not
a normal breast protein, was to perform
blocking studies with papain-soluble mem-
brane proteins from breast cancer, normal
breast tissue and a melanoma control.
Table VII shows that the LAI reactivity
of the LAI+ BBD patient is blocked onlyFALSE POSITIVE AND NEGATIVE LAI ACTIVITY
by the isolated papain-soluble breast-
cancer-membrane tumour antigen. The
reactivity of the breast-cancer patient is
similarly blocked. Both patients tested
with BBD who were LAI+ to the panel of
breast antigen had their leucocyte reac-
tivity blocked by the isolated papain-
soluble breast-cancer TSA.
Kinetics ofpositive LAI in BBD patients
The patients with benign breast disease
who were positive to the panel were
monitored by tube LAI assay. With one
exception, the LAI activity had disap-
peared within 2-4 months of the
surgical biopsy. The one exception was a
patient whose LAI reactivity disappeared
at 7 months.
Lack of LAI reactivity of close family
contactts
Laboratory personnel involved in hand-
ling breast-cancer tissue or blood from
patients with breast-cancer, and family
members living in the home of the
patient with breast-cancer were assayed
bv tube LAI. The 3 laboratory technicians
with 3- years of frequent contact with
breast-cancer extracts and blood pro-
ducts and members from 10 different
families showed no LAI activity to
extracts of breast cancer.
DISCUSSION
In a coded study, 17% and 28% of
Stage I and II breast-cancer patients were
initially LAI- (Lopez et al., 1978). Theo-
retically, the leucocytes of these patients
might, have been expected to display
antitumour immunity. The present study
showed that most of these initially LAI-
reacted to the panel of breast-cancer
extracts. Thus most patients with local-
ized breast cancer do exhibit systemic
antitumour immunity.
There appear to be 4 major reasons for
a negative LAI test in patients with
localized (Stage I and II) breast cancer.
First, some had a negative LAI test as a
result of experimental error of the assay.
Second, deterioration in the antigenic
activity of the extract can cause negative
results. The loss of antigenic activity is
often not an all-or-none phenomenon, and
is therefore frequently recognized only in
retrospect, when more patients than
usual have negative assays. The PBS
cancer extracts have a maximum "shelf-
life" of about 4-6 months when stored at
-40°C, and when the extracts are used
beyond 4 months more negative responses
are frequently obtained. Third, the breast-
cancer extract used as the initial test
antigen may not have the same antigen
as the patient's own tumour. Antigenic
heterogeneity, while it may exist in
breast cancers, does not, however, appear
to be a common problem. In contrast,
antigenic heterogeneity in lhepatoma of'
the liver appears to be common (Halliday
et al., personal communication). Fourth,
leucocytes from some patients may not
be responding immunologically to their
cancer and will not respond in the assay.
The leucocytes from one patient with
Stage I breast cancer, even when tested
with multiple breast-tumour extracts in-
cluding her own, showed no LAI activity.
Lack of reactivity to the tumour was not
due to failure of the tumour to express
TSAs, since an extract of this tumour had
specific antigen activity in the tube LAI
assay against leucocytes from other reac-
tive breast-cancer patients. The possibility
that the patient had undetected wide-
spread cancer and excess circulating TSA
that abrogated LAI activity (Grosser &
Thomson, 1976; Lopez & Thomson, 1978)
was not supported by blocking studies,
since her serum failed to block LAI-
reactive leucocytes from patients with
breast cancer. The tumour had high
levels of cortisol receptors (Fazekas &
MacFarlane, 1977) which concentrate cor-
tisol within the tumour. We have pre-
viously reported that patients' NAI
values and cortisol receptor concentration
in the tumours were inversely correlated,
and we speculated that high levels of
cortisol within breast cancers may impair
the afferent limb of the immune response
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(Fazekas et al., 1979). Nevertheless, since
the LAI activity of many patients with
Stage III and IV breast cancer is abroga-
ted by excess circulating TSA from the
large tumour burden, some patients with
Stage I and II cancer can be expected
also to lack LAI reactivity because they
have a more advanced stage of cancer
than was detected clinically. In the
present study, however, PBL from the
one patient who definitely showed no
LAI reactivity appeared not to react
for another reason.
The other problem encountered in in
vitro tube LAI assay was false-positive
LAI responses. Three per cent of control
subjects with either unrelated malignan-
cies or nonmalignant diseases were LAI+.
When these patients were tested against
the panel of antigens, most were shown to
be negative; i.e. the initial result was an
experimental error. In the 2 patients who
were positive to the panel, one had BBD
and ovarian cancer, and the benign
breast disease may have been the source
of antigenic stimulation, since ovarian
cancers have been used as tumour ex-
tracts without evidence of cross-reactivity
with breast-cancer, and other patients
with similar tumours have not reacted to
breast-cancer extracts. The explanation
for the male patient with a hernia who
had a positive LAI response to the panel
is unknown. He had no history of con-
tact with breast-cancer patients. In this
context, a number ofinvestigators (Burger
et al., 1977; G-raham-Pole et al., 1976;
Byers et al., 1975; Morton & Malmgren,
1968) have reported that close family
contacts of cancer patients may be
sensitized to the cancer since they react
in in vitro assays that measure anti-
tumour immunity. Although extensive
family studies were not undertaken,
no positive responses were recorded in the
10 families tested. In addition, 3 members
of the laboratory staff who have been
extensively exposed to tumour extracts
and products from breast-cancer patients
had no positive LAI response to breast-
cancer extracts.
In-hospital patients with benign breast
disease had a higher rate (12%) ofpositive
responses in the tube LAI assay (Flores
et al., 1977; Lopez et al., 1978) than
control subjects. By contrast, a control
group of patients with BBD tested
randomly from the outpatient mammo-
graphy clinic had a low rate (2%) of
LAI+ responses (Lopez et al., 1978).
The in-hospital patients with BBD were
admitted to hospital because in the
opinion of the surgeon the breast mass,
from the history and examination, was
thought to be cancer rather than benign
disease. Histological examination of the
excised breast tissues from the in-hospital
patients with BBD (both LAI+ and LAI-)
revealed that some of the breast tissue
from the positive responders had more
marked hyperplasia of the epithelium
and inflammatory infiltrates than that
from the negative responders. In no
instances, however, were there changes
that the pathologist scored as carcinoma
in situ (Grade 5).
Proof that extracts of the excised
breast masses were able to act similarly
to extracts of breast cancer in producing
antigen-induced LAI is not available,
because of ethical considerations. Never-
theless, the other evidence strongly sug-
gests that breast lesions from LAI+
patients that were histopathologically
benign expressed the TSA of breast
cancer. The LAI+ BBD patients had
cytophilic antitumour antibodies in their
serum that were able to arm normal
leucocytes to respond in an immunologi-
cally specific manner to extracts ofbreast-
cancer. The LAI+ leucocytes of the BBD
patients were blocked in an immuno-
logically specific manner by serum from
advanced breast-cancer patients. The leu-
cocytes showed LAI activity to extracts
of breast cancer and not to extracts of
fibrocystic disease from patients whose
leucocytes had no LAI activity. The
leucocytes from LAI+ patients with BBD
were blocked by papain-soluble breast-
cancer TSA isolated from the membrane
of breast-cancer cells (Thomson, 1978;FALSE POSITIVE AND NEGATIVE LAI ACTIVITY 683
Thomson et al., 1976) but the leucocytes
were not blocked by proteins isolated in
an identical manner from normal breast
tissue or malignant melanoma. After
excision ofthe breast mass, the kinetics of
the antitumour immune response of the
LAI+ patient with BBD were identical to
those of breast-cancer patients after
mastectomy (Flores et al., 1977; Lopez
et al., 1978). Moreover, the loss of LAI
activity after excision of the breast mass
suggests that the source of the antigenic
stimulus was confined to the lesion
removed and not present, at least in
enough quantity to evoke an immune
response, in the remaining breast tissue
which still contained fibrocystic disease.
In all 5 patients, the LAI response of the
LAI+ patient with BBD was identical to
that for breast-cancer patients. Hence,
the lesions of the LAI+ patients with
BBD appear to express a similar TSA to
that of unequivocal breast cancer.
Although in some of the patients there
was epithelial hyperplasia and atypia,
histologically these changes did not
amount to carcinoma in situ.
The biological implications of these
findings are intriguing. It would appear
that the breast tissue has undergone a
transformation typical ofcarcinoma, with-
out any morphological sign of unequi-
vocal malignancy. Whether this implies
an early, irretrievable step on the way to
invasive carcinoma, or whether this
change is reversible and is an expression
of unusual but controlled cell prolifera-
tion cannot be resolved.
Certainly, it is known that patients
with "benign" mammary dysplasia have
a higher incidence of breast-cancer (Mon-
son et al., 1976; Haagensen, 1977;
Donnelly et al., 1975). Again, in the
mouse angiogenesis, a property of car-
cinomas but not of resting mammary
gland, appears earlier than any morpho-
logical evidence of malignancy in mouse
papillomas which frequently progress to-
ward invasive carcinoma (Brem et al.,
1977).
The present study showed that most
patients with clinically detectable
localized cancer (Stage I and II) mani-
fested systemic antitumour immunity.
Conversely, with the exception of a few
patients of a select group of in-hospital
patients with benign breast disease, most
patients without breast cancer displayed
no LAI activity to breast-cancer antigens
and false-positive LAI responses were the
result of experimental error, with an
incidence of less than 5% against a single
extract. By the use of a panel of breast-
cancer antigens including testing the
patient against her own tumour, it was
possible to clarify, in most instances, false
LAI+ or LAI- responses. Unfortunately,
the use of a panel of antigens is too
tedious to be used for routine testing.
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